RISEUPTOHIV
RISEUPTOHIV
EDUCATION • COMMUNITY • RESOURCES
About Contact
ES HT
Quick Answer

Is there a once-a-day pill for HIV?

Answered in plain language, anchored to CDC, HIV.gov, and NIH.

Last reviewed:

Health information — Educational information, not medical advice. Talk with your healthcare provider about your care and treatment decisions.
← Home
Share this answer Facebook X WhatsApp Text Email LinkedIn Reddit Threads Bluesky

Yes. Many people can use a complete HIV treatment regimen in one tablet once a day. NIH recommends Biktarvy and, when its eligibility conditions are met, Dovato among initial options for most people. Other tablets are used in particular circumstances or as switches after viral suppression. The right choice depends on resistance, hepatitis B, other medicines, health needs and reliable access.[1][3][4]

What the 2026 guidelines actually recommend

The overall NIH adult and adolescent treatment guidelines were updated May 27, 2026; individual sections have their own dates. The current initial-regimen section is dated September 12, 2024. For people without previous long-acting cabotegravir PrEP use, it lists the following options with AI ratings, meaning strong recommendations supported by randomized trials:[1][2]

Dovato is not recommended as initial therapy when HIV RNA exceeds 500,000 copies/mL, hepatitis B is present, or treatment must start before relevant resistance and hepatitis B results are available. Other options for particular situations include Symtuza, Triumeq, Delstrigo and Odefsey. Triumeq requires a negative HLA-B*5701 test, consideration of cardiovascular risk, and additional hepatitis B treatment when needed. NIH lists Odefsey for initial treatment only with HIV RNA below 100,000 copies/mL and CD4 above 200 cells/mm³. After long-acting cabotegravir PrEP, integrase resistance testing guides treatment; NIH recommends boosted darunavir plus two NRTIs if starting before those results return.[1]

The single-tablet regimens available today

NIH’s medicine list and FDA approval records document these examples of complete once-daily tablets. An approval date does not mean a tablet is a preferred initial regimen for everyone:[5][4]

FDA approved Idvynso (doravirine/islatravir) on April 20, 2026. Its labeled use is to replace a stable regimen in adults with HIV RNA below 50 copies/mL, no history of virologic treatment failure and no known doravirine-resistance substitutions. It is taken once daily with or without food. Its interactions must be checked: lamivudine and emtricitabine are contraindicated with Idvynso. Genvoya, Stribild, Complera, Juluca and Idvynso are not listed as current NIH initial-regimen recommendations; absence from those tables does not by itself mean a person doing well on an existing regimen must change.[13][5][1]

Why one pill a day matters — and why it isn't automatic

NIH links once-daily dosing, low pill burden, manageable food requirements and tolerability with better adherence. It generally recommends a single tablet when clinically appropriate, while noting that high-quality evidence to recommend single tablets definitively is limited. Shared decisions should include what a person can consistently obtain and take.[3]

A regimen you can obtain and take consistently is the practical goal. Two affordable, suitable tablets may work better for your circumstances than one tablet you cannot reliably access. If pill count, side effects, cost or privacy creates difficulty, bring that problem to your care team.[3]

Food rules and other differences between the pills

Food and interaction instructions differ. Biktarvy and Dovato can be taken with or without food, but mineral supplements and antacids may need specific timing. Odefsey requires a meal and cannot be combined with proton pump inhibitors; Symtuza is taken with food. Ask your pharmacist to review the exact tablet and everything else you take.[10][11][12][6][1]

TAF generally has fewer bone and kidney toxicities than TDF, while TDF is associated with lower lipid levels. Safety, cost and access matter in the choice. NIH identifies dolutegravir, bictegravir and boosted darunavir as medicines with high barriers to resistance and recommends considering these regimens when adherence has been difficult.[1][3]

Florida: ADAP coverage and 2026 changes

The Florida ADAP formulary dated July 2026 covers Biktarvy, Dovato, Symtuza, Triumeq, Odefsey, Delstrigo, and Juluca — plus the injectables Cabenuva and Sunlenca — noting that unless otherwise marked, all brands, strengths, and dosage forms may be ordered pending wholesaler availability[7].

Florida’s 2026 ADAP changes affected medication access. Chapter 2026-4, approved March 24, appropriated $30,901,933 and set a 400%-of-poverty eligibility standard through June 30, 2026. Those time-limited provisions should not be mistaken for today’s complete program rules. Florida DOH currently lists a 0–400% income threshold and says Biktarvy and Descovy returned to the formulary July 1 for direct medication assistance and the CVS Caremark copay/deductible program.[9][8]

Florida DOH lists HIV status, medication need, income and insurance criteria for ADAP eligibility. Uninsured eligible clients may receive direct medication assistance; eligible insured clients may receive medication copay and deductible help. The program says it does not currently pay insurance premiums. Contact the ADAP Help Desk at 844-381-2327 or Prime Therapeutics at 833-604-0925 for enrollment and direct-medication questions. Confirm eligibility and the specific medication before relying on coverage.[8]

Related questions

What is the most commonly recommended once-a-day HIV pill?

Biktarvy and Dovato are among NIH’s recommended initial options, but Dovato has important restrictions, including high baseline viral load, hepatitis B and pending test results. Prior long-acting cabotegravir PrEP also changes the resistance-testing and initial-treatment pathway. Your clinician should match the regimen to your test results, other medicines and access.[1]

Is there a new once-daily HIV pill in 2026?

Yes. FDA approved Idvynso on April 20, 2026 as a once-daily replacement regimen for adults already suppressed below 50 copies/mL on stable treatment, with no history of virologic treatment failure or known doravirine resistance. It is a switch option with specific interaction restrictions, including no coadministration with lamivudine or emtricitabine.[5][13]

Do I have to take my HIV pill with food?

It depends on the medicine. Biktarvy and Dovato can be taken with or without food; Odefsey requires a meal, and Symtuza requires food. Antacids, mineral supplements and acid-reducing drugs can create additional restrictions, so check your exact regimen with a pharmacist.[6][10][11][12]

Is one pill always better than two?

Not automatically. NIH generally recommends a single tablet when clinically appropriate, but acknowledges limited high-quality evidence for recommending it definitively. The best practical regimen is effective for your HIV and one you can reliably obtain and take.[3]

Treatment Hub
How modern HIV treatment works, from first prescription to lifelong suppression.
How long does it take to become undetectable?
What to expect in the first weeks and months on treatment.
Is undetectable really untransmittable?
The evidence behind U=U and the conditions it depends on.
I just tested positive — what do I do?
First steps, first appointments, and what actually happens next.
Policy & Advocacy
ADAP, Ryan White, and the Florida funding fights that shape access.
Last reviewed: September 2026 by the RiseUpToHIV team. Educational content only — not medical advice.

References & Sources

  1. NIH — Initial Combination Antiretroviral Regimens, section reviewed September 12, 2024; checked September 21, 2026. Source. ↩↩↩↩↩ ↩ ↩ ↩ ↩
  2. HHS/NIH — What's New in the Adult and Adolescent Antiretroviral Guidelines. Guideline update dates, including the May 27, 2026 revision. ↩
  3. NIH — Adherence to the Continuum of Care: regimen choice, access, single-tablet recommendation and high resistance barriers. Source. ↩↩↩↩ ↩ ↩
  4. NIH HIVinfo — FDA-Approved HIV Medicines. Brand names, components, and FDA approval dates for each single-tablet regimen. ↩ ↩
  5. FDA — Idvynso (doravirine/islatravir) approval letter, NDA 216964, April 20, 2026. Primary approval document and the exact indication wording for the 2026 addition. ↩ ↩ ↩ ↩
  6. NIH MedlinePlus — Bictegravir, Emtricitabine, and Tenofovir Alafenamide (Biktarvy). Patient-facing dosing and food information. ↩ ↩
  7. Florida Department of Health — ADAP Formulary, July 2026. Current list of antiretrovirals covered by Florida's AIDS Drug Assistance Program. ↩
  8. Florida Department of Health — AIDS Drug Assistance Program. Eligibility criteria, the July 1, 2026 Biktarvy restoration, and ADAP contact numbers. ↩ ↩
  9. Laws of Florida — Chapter 2026-4, approved March 24, 2026: temporary ADAP appropriation and eligibility provisions. Source. ↩
  10. MedlinePlus — Dolutegravir and lamivudine. Source. Checked September 21, 2026. ↩ ↩
  11. MedlinePlus — Emtricitabine, rilpivirine and tenofovir alafenamide. Source. Checked September 21, 2026. ↩ ↩
  12. MedlinePlus — Darunavir, cobicistat, emtricitabine and tenofovir alafenamide. Source. Checked September 21, 2026. ↩ ↩
  13. FDA — Idvynso prescribing information, April 2026. Source. Checked September 21, 2026. ↩ ↩

Community publications like POZ, Positively Aware, and TheBody inform framing and lived-experience context on RiseUpToHIV. Every clinical, epidemiological, or public-health claim above is anchored to a primary source.

Search RiseUpToHIV